PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
On 14th April 2014
During the forecast period from 20122022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
Buy this report OR Know more : http://www.jsbmarketresearch.com/healthcare-medical/r-PharmaPoint-Ulcerative-Colitis-Global-Drug-Forecast-and-Market-Analysis-to-2022-89051
Overall, major barriers to the growth of the UC market include Remicade and Humira losing patent protection in the mid-forecast Austerity measures favoring generic prescribing
Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US In 2012, GlobalData estimates that the global UC market reached $4.2 billion across the 10 healthcare markets covered in our forecast: the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China, and India. By the end of the forecast period, in 2022, sales across these markets will grow steadily to reach $6.6 billion, representing a Compound Annual Growth Rate (CAGR) of 4.8% over the 10-year timeframe .
Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022. Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics markets. Pipeline analysis: comprehensive data split across different phases, emerging novel trends...
Please join StudyMode to read the full document